Format

Send to

Choose Destination
See comment in PubMed Commons below
Ther Clin Risk Manag. 2007 Oct;3(5):741-9.

Naltrexone long-acting formulation in the treatment of alcohol dependence.

Author information

  • 1Department of Psychiatry and Neurobehavioral Sciences, University of Virginia Charlottesville, VA, USA.

Abstract

While oral naltrexone has a demonstrated ability to decrease alcohol reinforcement, it also has pharmacotherapeutic limitations, such as a small treatment effect size, adverse events, and plasma level fluctuations. The pharmacokinetic profile of naltrexone could be enhanced by intramuscular administration, which would sustain its release over several weeks and keep plasma levels relatively constant, ie, low enough to minimize side effects but high enough to reduce drinking. Vivitrex((R))/Vivitrol((R)) and Naltrel((R)) are injectable naltrexone depot formulations that have been tested as possible medications for treating alcohol dependence. Their adverse-event profiles appear to be less severe than that of oral naltrexone. Vivitrex((R))/Vivitrol((R)) has demonstrated efficacy at decreasing heavy drinking among alcohol-dependent males. Naltrel((R)) helped to promote abstinence and decrease the incidence of relapse in two samples of alcohol-dependent subjects. The data on a third formulation, Depotrex((R)), are still limited. All three formulations require further study of their efficacy.

KEYWORDS:

Depotrex®; Naltrel®; Vivitrex®; Vivitrol®; alcohol dependence; depot; naltrexone

PMID:
18472999
PMCID:
PMC2376083
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center